Humana (HUM) Reaches New 1-Year High and Low on Analyst Upgrade
Humana (NYSE:HUM)’s share price reached a new 52-week high and low on Tuesday after Argus raised their price target on the stock from $270.00 to $330.00. Argus currently has a buy rating on the stock. Humana traded as low as $297.40 and last traded at $295.11, with a volume of 474566 shares trading hands. The stock had previously closed at $289.95.
Several other equities analysts have also recently weighed in on HUM. Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $316.00 price target on the stock in a report on Friday. Piper Jaffray reissued a “buy” rating and set a $313.00 price target on shares of Humana in a report on Wednesday, April 4th. ValuEngine raised Humana from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Deutsche Bank increased their price target on Humana from $259.00 to $270.00 and gave the company a “hold” rating in a report on Friday, February 9th. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $250.00 price target on shares of Humana in a report on Wednesday, February 7th. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $277.05.
In other Humana news, insider M Todoroff Christopher sold 16,389 shares of the stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $273.37, for a total value of $4,480,260.93. Following the completion of the sale, the insider now owns 13,447 shares in the company, valued at approximately $3,676,006.39. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce D. Broussard sold 14,075 shares of the stock in a transaction on Monday, February 26th. The stock was sold at an average price of $274.32, for a total value of $3,861,054.00. Following the completion of the sale, the chief executive officer now owns 113,896 shares of the company’s stock, valued at approximately $31,243,950.72. The disclosure for this sale can be found here. Insiders sold a total of 31,660 shares of company stock valued at $8,668,218 over the last 90 days. 0.60% of the stock is currently owned by company insiders.
The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.85 and a current ratio of 1.85. The firm has a market cap of $39,600.76, a price-to-earnings ratio of 25.35, a PEG ratio of 1.55 and a beta of 0.97.
Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, February 7th. The insurance provider reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $2.00 by $0.06. Humana had a net margin of 4.55% and a return on equity of 16.13%. The business had revenue of $13.19 billion during the quarter, compared to the consensus estimate of $13.14 billion. During the same period in the previous year, the firm posted $2.34 earnings per share. The company’s quarterly revenue was up 2.4% compared to the same quarter last year. analysts forecast that Humana will post 13.86 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, April 27th. Investors of record on Friday, March 30th will be issued a $0.50 dividend. The ex-dividend date of this dividend is Wednesday, March 28th. This is a boost from Humana’s previous quarterly dividend of $0.40. This represents a $2.00 annualized dividend and a yield of 0.68%. Humana’s dividend payout ratio is currently 17.08%.
COPYRIGHT VIOLATION NOTICE: “Humana (HUM) Reaches New 1-Year High and Low on Analyst Upgrade” was first published by Daily Political and is the property of of Daily Political. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.dailypolitical.com/2018/04/17/humana-hum-reaches-new-1-year-high-and-low-on-analyst-upgrade.html.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.